Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.44 |
| ▸ | HCRTR1 | O43613 | 17/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14843975 | 0.98 | CSNK2A1 (0.46) | CSNK2A1HCRTR2HCRTR1CYP3A4KDM4E | |
| SCHEMBL20551182 | 0.87 | HCRTR1 (0.50) | CSNK2A1HCRTR2HCRTR1KDM4E | |
| SCHEMBL29588462 | 0.85 | HCRTR1 (0.51) | CSNK2A1HCRTR2HCRTR1KDM4E | |
| SCHEMBL16846509 | 0.85 | HCRTR1 (0.44) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL934700 | 0.85 | HCRTR1 (0.51) | CSNK2A1HCRTR2HCRTR1KDM4E | |
| SCHEMBL20550637 | 0.83 | HCRTR1 (0.50) | CSNK2A1HCRTR2HCRTR1KDM4E | |
| Potassium Ion SCHEMBL20551716 | 0.82 | HCRTR2 (0.42) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL17069777 | 0.81 | HCRTR1 (0.42) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL16040983 | 0.81 | CYP46A1 (0.49) | HCRTR2HCRTR1CYP3A4 | |
| SCHEMBL18197650 | 0.81 | HCRTR1 (0.44) | HCRTR2HCRTR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11124488-B2 | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-09-21 | — | — | US | disclosed |
| EP-3619199-B1 | PREPARATION OF 2-([1,2,3]TRIAZOL-2-YL)-BENZOIC ACID DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210114997-A1 | PREPARATION OF 2-([1,2,3]TRIAZOL-2-YL)-BENZOIC ACID DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3619199-A1 | PREPARATION OF 2-([1,2,3]TRIAZOL-2-YL)-BENZOIC ACID DERIVATIVES | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-11 | — | — | EP | disclosed |
| CN-110612291-A | Preparation of 2- ([1,2,3] triazol-2-yl) -benzoic acid derivatives | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018202689-A1 | PREPARATION OF 2-([1,2,3]TRIAZOL-2-YL)-BENZOIC ACID DERIVATIVES | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11124488-B2 | Preparation of 2-([1,2,3]triazol-2-yl)-benzoic acid derivatives | KCNK5, KCNJ2, KCNK2 | CSNK2A1 122/4885HCRTR2 3339/4885HCRTR1 4534/4885 |
| US-20210114997-A1 | PREPARATION OF 2-([1,2,3]TRIAZOL-2-YL)-BENZOIC ACID DERIVATIVES | KCNK5, KCNJ2, KCNK2 | CSNK2A1 122/4885HCRTR2 3339/4885HCRTR1 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.